Translation and validation

H. Bart van der Worp, David W. Howells, Emily S. Sena, et al. Can Animal Models of Disease Reliably Inform Human Studies? PLOS Medicine. 7(3):e1000245. doi:10.1371/journal.pmed.1000245

Alper Öztürk, Halis Atıl Atilla. In Musculoskeletal Research, Too Many Animals are Being Harmed for Too Small a Return. Clinical Orthopaedics and Related Research. 482(5):899-900. doi:10.1097/CORR.0000000000003037

Clifford S. Deutschman. Translating Animal Studies to Human Disease: Language Matters*. Critical Care Medicine. 52(3):518-520. doi:10.1097/CCM.0000000000006167

Guilherme S. Ferreira, Désirée H. Veening-Griffioen, Wouter P. C. Boon, et al. A standardised framework to identify optimal animal models for efficacy assessment in drug development. PLOS ONE. 14(6):e0218014. doi:10.1371/journal.pone.0218014

Benjamin V. Ineichen, Eva Furrer, Servan L. Grüninger, Wolfgang E. Zürrer, Malcolm R. Macleod. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLOS Biology. 22(6):e3002667. doi:10.1371/journal.pbio.3002667

René Aquarius, Merel van de Voort, Hieronymus D. Boogaarts, P. Manon Reesink, Kimberley E. Wever. High prevalence of articles with image-related problems in animal studies of subarachnoid hemorrhage and low rates of correction by publishers. PLOS Biology. 23(10):e3003438. doi:10.1371/journal.pbio.3003438

Linda Bunschoten. The Real Cost of Delays in Drug Development and the Role of RBQM and QbD. https://cyntegrity.com/the-real-cost-of-delays-in-drug-development-and-the-role-of-rbqm-and-qbd.